JP2015508757A5 - - Google Patents

Download PDF

Info

Publication number
JP2015508757A5
JP2015508757A5 JP2014556052A JP2014556052A JP2015508757A5 JP 2015508757 A5 JP2015508757 A5 JP 2015508757A5 JP 2014556052 A JP2014556052 A JP 2014556052A JP 2014556052 A JP2014556052 A JP 2014556052A JP 2015508757 A5 JP2015508757 A5 JP 2015508757A5
Authority
JP
Japan
Prior art keywords
seq
antibody
variable region
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014556052A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508757A (ja
JP6405242B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/052439 external-priority patent/WO2013117647A1/en
Publication of JP2015508757A publication Critical patent/JP2015508757A/ja
Publication of JP2015508757A5 publication Critical patent/JP2015508757A5/ja
Application granted granted Critical
Publication of JP6405242B2 publication Critical patent/JP6405242B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014556052A 2012-02-07 2013-02-07 Ｍｉｃａ結合剤 Active JP6405242B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261595902P 2012-02-07 2012-02-07
US61/595,902 2012-02-07
US201261625841P 2012-04-18 2012-04-18
US61/625,841 2012-04-18
PCT/EP2013/052439 WO2013117647A1 (en) 2012-02-07 2013-02-07 Mica binding agents

Publications (3)

Publication Number Publication Date
JP2015508757A JP2015508757A (ja) 2015-03-23
JP2015508757A5 true JP2015508757A5 (https=) 2016-03-31
JP6405242B2 JP6405242B2 (ja) 2018-10-17

Family

ID=47714068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014556052A Active JP6405242B2 (ja) 2012-02-07 2013-02-07 Ｍｉｃａ結合剤

Country Status (11)

Country Link
US (2) US10577416B2 (https=)
EP (1) EP2812027A1 (https=)
JP (1) JP6405242B2 (https=)
CN (1) CN104244977A (https=)
AU (1) AU2013218017B2 (https=)
BR (1) BR112014019611A2 (https=)
CA (1) CA2862101A1 (https=)
IL (1) IL233793B (https=)
RU (1) RU2656183C2 (https=)
SG (1) SG11201404177PA (https=)
WO (1) WO2013117647A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2925654T3 (es) 2011-09-30 2022-10-19 Dana Farber Cancer Inst Inc Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA)
EP2812027A1 (en) 2012-02-07 2014-12-17 Innate Pharma Mica binding agents
JP6518199B6 (ja) 2013-03-15 2019-06-12 ノヴェロジックス・バイオテクノロジー，インコーポレーテッド Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
KR20150130462A (ko) 2013-03-15 2015-11-23 다나-파버 캔서 인스티튜트 인크. 치료 펩티드
EA201691078A1 (ru) * 2013-12-06 2017-01-30 Дана-Фарбер Кэнсер Инститьют, Инк. Терапевтические пептиды
WO2015139020A2 (en) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
EP4043474A1 (en) * 2014-12-05 2022-08-17 Xyphos Biosciences Inc. Insertable variable fragments of antibodies and modified a1-a2 domains of nkg2d ligands
US10744157B2 (en) 2015-03-26 2020-08-18 The Trustees Of Dartmouth College Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
AU2016299166B2 (en) 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
KR20180088458A (ko) * 2015-12-04 2018-08-03 다나-파버 캔서 인스티튜트 인크. 암의 치료를 위한 mica/b 알파 3 도메인의 백신접종
WO2017147247A1 (en) * 2016-02-23 2017-08-31 Pires Eusebio S Anti-sas1b antibodies and methods of use
RU2018128215A (ru) * 2016-03-15 2020-04-15 Иннейт Фарма Антитела против mica
CN107779433A (zh) * 2016-08-30 2018-03-09 天津市康婷生物工程有限公司 便捷的刺激nk细胞增殖和分化的饲养层制备方法
CA3040421A1 (en) * 2016-10-19 2018-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
CN107964041B (zh) * 2016-10-20 2023-08-01 中国科学院广州生物医药与健康研究院 高稳定性和高亲和力的dmic及其制法
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
US20200023071A1 (en) 2017-02-06 2020-01-23 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
US11421032B2 (en) 2017-05-22 2022-08-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for inhibition of MICA/B shedding
AU2018298673A1 (en) * 2017-07-10 2019-12-19 Innate Pharma Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
WO2019068907A1 (en) * 2017-10-06 2019-04-11 Innate Pharma RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
MX2021001254A (es) 2018-07-31 2021-05-12 Cullinan Mica Corp Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso.
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
AU2020336023A1 (en) * 2019-08-23 2022-03-03 Northwestern University Materials and methods for activating antigen-specific T cell responses
CA3160759A1 (en) * 2019-12-05 2021-06-10 Vycellix, Inc. Modulators of the immune escape mechanism for universal cell therapy
CN111471099B (zh) * 2020-03-31 2022-04-12 长沙学院 MICA胞外区突变体及其筛选的方法、scFv-MICA融合抗体及其制备方法和应用
CN111718416B (zh) * 2020-06-25 2022-04-01 菲鹏生物股份有限公司 抗硫氧还蛋白的抗体、其应用和诊断试剂盒
CA3184940A1 (en) 2020-07-07 2022-01-13 Jennifer Donglan WU Mic antibodies and binding agents and methods of using the same
CN116547301A (zh) 2020-08-10 2023-08-04 先天制药公司 使用抗体进行的细胞表面mica和micb检测
CN112694532B (zh) * 2021-01-12 2023-04-18 倍而达药业（苏州）有限公司 抗Siglec-15的抗体或其抗原结合片段及应用
CN113502265B (zh) * 2021-05-25 2024-05-28 昭泰英基生物医药（香港）有限公司 将t细胞重编程为类nk细胞的诱导剂及其应用
CN118307672B (zh) * 2021-07-14 2026-04-17 浙江大学 一种抗人MICA/B α3区的抗体及其应用
CN114369162B (zh) * 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
CN114369161B (zh) * 2021-12-28 2023-06-23 合肥天港免疫药物有限公司 Mica抗体及其应用
CN118027195B (zh) * 2023-05-06 2025-07-04 合肥天港免疫药物有限公司 亲和力成熟的mica抗体及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO1996030511A1 (en) * 1995-03-29 1996-10-03 The Immunogenetics Research Foundation Incorporated Polymorphic and multicopy members of mhc gene families
CA2275141A1 (en) 1996-10-29 1998-05-07 Thomas Spies Cell stress regulated human mhc class i gene
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003225093A1 (en) 2002-04-22 2003-11-03 Fred Hutchinson Cancer Research Center Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005110474A2 (en) 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
US20090208500A1 (en) 2005-06-03 2009-08-20 Genentech, Inc. Method of producing antibodies with improved function
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1949107A1 (en) 2005-11-03 2008-07-30 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by nkg2d-positive cd4-positive cells
FR2894982A1 (fr) 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
BRPI0707290A2 (pt) 2006-01-17 2011-08-16 Biolex Therapeutics Inc composições e métodos para humanização e otimização de n-glicanas em plantas
CA2644903A1 (en) 2006-03-10 2007-09-20 Macrogenics, Inc. Identification and engineering of antibodies with variant heavy chains and methods of using same
US7786270B2 (en) 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
CA2665090A1 (en) * 2006-09-22 2008-03-27 Dana-Farber Cancer Institute, Inc. Methods for treating mica-related disorders
CA2685056C (en) * 2007-04-23 2015-08-25 Fred Hutchinson Cancer Research Center Negative immunomodulation of immune responses by erp5
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
CA2822366A1 (en) 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
ES2925654T3 (es) 2011-09-30 2022-10-19 Dana Farber Cancer Inst Inc Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA)
EP2812027A1 (en) 2012-02-07 2014-12-17 Innate Pharma Mica binding agents
RU2018128215A (ru) 2016-03-15 2020-04-15 Иннейт Фарма Антитела против mica

Similar Documents

Publication Publication Date Title
JP2015508757A5 (https=)
JP7303314B2 (ja) Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞
TWI664289B (zh) 針對細胞內抗原之單域抗體
JP2020023523A5 (https=)
US10925969B2 (en) Anti-BCMA polypeptides and proteins
ES2649155T3 (es) Anticuerpos anti-OX40 y procedimientos de uso de los mismos
IL268620B2 (en) Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment
FI3946621T3 (fi) Mage a4 -t-solureptoreja
JP2017505622A5 (https=)
CN110945120A (zh) 测量纳米药物中受体-配体相互作用的效力的测定
JP2019531084A5 (https=)
JP2008516970A5 (https=)
JP2017522903A5 (https=)
JP2014039548A5 (https=)
CN112119099A (zh) 三特异性抗原结合蛋白
RU2014131317A (ru) Связывающие mica агенты
JP2016539096A5 (https=)
JP2017527275A5 (https=)
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
JP2010500005A5 (https=)
JP2013506425A5 (https=)
FI3443010T3 (fi) Uusia anti-sirp -vasta-aineita ja niiden terapeuttisia sovelluksia
JP2020503841A5 (https=)
WO2019144677A1 (zh) 抗ox40抗体及其用途
CN110475788A (zh) 抗ceacam1抗体及其应用